Literature DB >> 18025118

Human pre-elafin inhibits a Pseudomonas aeruginosa-secreted peptidase and prevents its proliferation in complex media.

Audrey Bellemare1, Nathalie Vernoux, Dany Morisset, Yves Bourbonnais.   

Abstract

Pseudomonas aeruginosa is a life-threatening opportunist human pathogen frequently associated with lung inflammatory diseases, namely, cystic fibrosis. Like other species, this gram-negative bacteria is increasingly drug resistant. During the past decade, intensive research efforts have been focused on the identification of natural innate defense molecules with broad antimicrobial activities, collectively known as antimicrobial peptides. Human pre-elafin, best characterized as a potent inhibitor of neutrophil elastase with anti-inflammatory properties, was also shown to possess antimicrobial activity against both gram-positive and gram-negative bacteria, including P. aeruginosa. Its mode of action was, however, not known. Using full-length pre-elafin, each domain separately, and mutated variants of pre-elafin with attenuated antipeptidase activity toward neutrophil elastase, we report here that both pre-elafin domains contribute, through distinct mechanisms, to its antibacterial activity against Pseudomonas aeruginosa. Most importantly, we demonstrate that the whey acidic protein (WAP) domain specifically inhibits a secreted peptidase with the characteristics of arginyl peptidase (protease IV). This is the first demonstration that a human WAP-motif protein inhibits a secreted peptidase to prevent bacterial growth in vitro. Since several WAP-motif proteins from various species demonstrate antimicrobial function with variable activities toward bacterial species, we suggest that this mechanism may be more common than initially anticipated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025118      PMCID: PMC2224742          DOI: 10.1128/AAC.00585-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Pseudomonas deficient in protease IV has significantly reduced corneal virulence.

Authors:  L S Engel; J A Hobden; J M Moreau; M C Callegan; J M Hill; R J O'Callaghan
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-07       Impact factor: 4.799

2.  Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection.

Authors:  A M Cantin; D E Woods
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

Review 3.  The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core.

Authors:  J Schalkwijk; O Wiedow; S Hirose
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

4.  Antibacterial activity of antileukoprotease.

Authors:  P S Hiemstra; R J Maassen; J Stolk; R Heinzel-Wieland; G J Steffens; J H Dijkman
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

5.  Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens.

Authors:  A J Simpson; A I Maxwell; J R Govan; C Haslett; J M Sallenave
Journal:  FEBS Lett       Date:  1999-06-11       Impact factor: 4.124

6.  Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.

Authors:  M J Richards; J R Edwards; D H Culver; R P Gaynes
Journal:  Crit Care Med       Date:  1999-05       Impact factor: 7.598

7.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

8.  Mitochondrial creatine kinase interaction with phospholipid vesicles.

Authors:  M J Vacheron; E Clottes; C Chautard; C Vial
Journal:  Arch Biochem Biophys       Date:  1997-08-15       Impact factor: 4.013

Review 9.  Structural, biochemical, and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI.

Authors:  H O Molhuizen; J Schalkwijk
Journal:  Biol Chem Hoppe Seyler       Date:  1995-01

10.  Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema.

Authors:  Alain Doucet; Dominique Bouchard; Marie France Janelle; Audrey Bellemare; Stéphane Gagné; Guy M Tremblay; Yves Bourbonnais
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

View more
  9 in total

1.  Functional characterization of polymorphisms in the peptidase inhibitor 3 (elafin) gene and validation of their contribution to risk of acute respiratory distress syndrome.

Authors:  Paula Tejera; D Shane O'Mahony; Caroline A Owen; Yongyue Wei; Zhaoxi Wang; Kushagra Gupta; Li Su; Jesus Villar; Mark Wurfel; David C Christiani
Journal:  Am J Respir Cell Mol Biol       Date:  2014-08       Impact factor: 6.914

2.  Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases.

Authors:  Nicolas Guyot; Gudmundur Bergsson; Marcus W Butler; Catherine M Greene; Sinéad Weldon; Efrat Kessler; Rodney L Levine; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  Biol Chem       Date:  2010-06       Impact factor: 3.915

Review 3.  Cytokine-mediated regulation of antimicrobial proteins.

Authors:  Jay K Kolls; Paul B McCray; Yvonne R Chan
Journal:  Nat Rev Immunol       Date:  2008-11       Impact factor: 53.106

Review 4.  New antimicrobial strategies in cystic fibrosis.

Authors:  Mireille van Westreenen; Harm A W M Tiddens
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

5.  Structural and antimicrobial properties of human pre-elafin/trappin-2 and derived peptides against Pseudomonas aeruginosa.

Authors:  Audrey Bellemare; Nathalie Vernoux; Sébastien Morin; Stéphane M Gagné; Yves Bourbonnais
Journal:  BMC Microbiol       Date:  2010-10-08       Impact factor: 3.605

6.  Induction of antimicrobial peptides secretion by IL-1β enhances human amniotic membrane for regenerative medicine.

Authors:  Fatemeh A Tehrani; Khashayar Modaresifar; Sara Azizian; Hassan Niknejad
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

Review 7.  Pseudomonas aeruginosa Keratitis: Protease IV and PASP as Corneal Virulence Mediators.

Authors:  Richard O'Callaghan; Armando Caballero; Aihua Tang; Michael Bierdeman
Journal:  Microorganisms       Date:  2019-08-22

Review 8.  Transglutaminase 2 as a Marker for Inflammation and Therapeutic Target in Sepsis.

Authors:  Ting Su; Xian-Yang Qin; Yutaka Furutani
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

9.  Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment.

Authors:  Thomas S Wilkinson; Kevin Dhaliwal; Thomas W Hamilton; Alexander F Lipka; Lesley Farrell; Donald J Davidson; Rodger Duffin; Andrew Conway Morris; Chris Haslett; John R W Govan; Christopher D Gregory; Jean-Michel Sallenave; A John Simpson
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.